Ãå±±½ûµØ

• For Print
• June 2, 2023

Ãå±±½ûµØ. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO^®), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States.

Major poster presentations include new data about the effects of lemborexant on obstructive sleep apnea (poster numbers: #298, 299 and 300).

Eisai considers neurology, including insomnia, a therapeutic area of focus. Eisai strives to create innovative products as soon as possible in therapeutic areas with high unmet medical needs, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

• • • SLEEP 2023 Poster Presentations

      *You can scroll to the left or right here

      Asset and Presentation Details (Time EDT)	Title
      Lemborexant Poster #297 Monday, June 5, 12:00 - 13:15	Long-term Efficacy of Lemborexant on Objective Sleep Measures in Clinical Practice
      Lemborexant Poster #298 Monday, June 5, 17:00 – 18:00	Effect of Lemborexant on Sleep Architecture in Subjects with Comorbid Insomnia and Mild Obstructive Sleep Apnea from a Ph 3 Trial
      Lemborexant Poster #299 Monday, June 5, 12:00 - 13:15	The Effect of Lemborexant on Polysomnographic Sleep Parameters in Adults with Mild, Moderate, or Severe Obstructive Sleep Apnea
      Lemborexant Poster #300 Monday, June 5, 17:00 – 18:00	Effect of Lemborexant on Sleep Architecture in Adult and Elderly Subjects with Mild to Severe Obstructive Sleep Apnea
      Lemborexant Poster #301 Monday, June 5, 12:00 - 13:15	Shifts in Daytime Functioning Items on the Insomnia Severity Scale with Lemborexant after 6 Months of Treatment
      Lemborexant Poster #302 Monday, June 5, 17:00 – 18:00	Differential Effect of Lemborexant and Zolpidem on Wake Across the Night in Patients with Insomnia Disorder
      Lemborexant Poster #303 Monday, June 5, 12:00 – 13:15	Impact of Lemborexant on Daytime Ratings of Sleepiness/Alertness in Subjects with Insomnia Disorder and Baseline Sleepiness
      Narcolepsy general Poster #248 Monday, June 5, 17:00 – 18:00	Burden of Narcolepsy in Japan: A Nationwide Real-world Database Study from The Perspectives of Direct Medical Cost and Comorbidity

      〶Ä〶Ä〶Ä〶Ä〶Ä

      Media Inquiries

      Public Relations Department

      Ãå±±½ûµØ.

      +81-(0)3-3817-5120

       

      Eisai Inc. (U.S.)

      TEL: +551-305-0050

      Christopher_Vancheri@eisai.com

      &²Ô²ú²õ±è;〶Ä

      〶Ä

      [Notes to editors]

      1. Ãå±±½ûµØ Lemborexant (product name: DAYVIGO)

      Lemborexant, an orexin receptor antagonist, is Eisai’s in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant’s potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in over 15 countries including Japan, the United States, Canada, Australia and countries in Asia.

• Full text